Depression-like effects induced by chronic unpredictable mild stress in mice are rapidly reversed by a partial negative allosteric modulator of mGlu5 receptor, M-5MPEP
Open Access
- 30 November 2024
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 242 (6) , 1259-1273
Abstract
Rationale: Due to the numerous limitations of ketamine as a rapid-acting antidepressant drug (RAAD), research is still being conducted to find an effective and safe alternative to this drug. Recent studies indicate that the partial mGlu5 receptor negative allosteric modulator (NAM), 2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridine (M-5MPEP), has therapeutic potential as an antidepressant. Objectives: The study aimed to investigate the potential rapid antidepressant-like effect of M-5MPEP in a mouse model of depression and to determine the mechanism of this action. Methods: Chronic unpredictable mild stress (CUMS) was used as an animal model of depression. The effects of single and four-day administration of M-5MPEP on CUMS-induced animal behaviors reflecting anhedonia, apathy, and helplessness were studied. Western blot was applied to measure the levels of proteins potentially involved in a rapid antidepressant effect, including mammalian target of rapamycin (mTOR), eukaryotic elongation factor 2 (eEF2), tropomyosin receptor kinase B (TrkB), and serotonin transporter (SERT), both in the hippocampus and the prefrontal cortex (PFC). Furthermore, excitatory synaptic transmission and long-term potentiation (LTP) were measured in the medial PFC (mPFC). Results: We showed that M-5MPEP administration for four consecutive days abolished CUMS-induced apathy- and anhedonia-like symptoms in a mouse model of depression. We also found that these effects were accompanied by changes in hippocampal TrkB levels and mTOR and eEF2 levels in the PFC. Using electrophysiological techniques, we showed that the four-day M-5MPEP treatment reversed chronic stress-induced increases in excitatory synaptic potential and CUMS-impaired LTP in the mPFC. Conclusions: Partial mGlu5 receptor NAM, M-5MPEP, appears to be a potentially effective new RAAD and deserves further study.Keywords
Funding Information
- Narodowe Centrum Nauki (2017/27/B/NZ7/01873)
This publication has 51 references indexed in Scilit:
- Subchronic administration of scopolamine reverses UCMS-induced behavior in mice via eEF2 protein dephosphorylationPharmacological Reports, 2024
- Partial mGlu5 receptor NAM, M-5MPEP, induces rapid and sustained antidepressant-like effects in the BDNF-dependent mechanism and enhances (R)-ketamine action in micePharmacological Reports, 2024
- Antidepressant-like activity of hyperforin and changes in BDNF and zinc levels in mice exposed to chronic unpredictable mild stressBehavioural Brain Research, 2019
- Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depressionPsychopharmacology, 2016
- Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of ratsBehavioural Brain Research, 2015
- A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive DisorderBiological Psychiatry, 2014
- Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanismPsychopharmacology, 2013
- Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant DepressionBiological Psychiatry, 2010
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major DepressionArchives of General Psychiatry, 2006
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in HumansArchives of General Psychiatry, 1994